Methyl 2-(3-acetyl-5-(pyrimidin-2-ylmethoxy)-1H-indazol-1-yl)acetate → Tert-butyl 2-(3-cyano-5-(pyrimidin-2-ylmethoxy)-1H-indazol-1-yl)acetate
反応式
[C:1]([O:5][C:6](=[O:24])[CH:7](C(C)(C)C)[N:8]1[C:16]2[C:11](=[CH:12][C:13]([OH:17])=[CH:14][CH:15]=2)[C:10]([C:18]#[N:19])=[N:9]1)([CH3:4])([CH3:3])[CH3:2].C(C1C2C(=CC=C(O[CH2:38][C:39]3[N:44]=[CH:43][CH:42]=[CH:41][N:40]=3)C=2)N(CC(OC)=O)N=1)(=O)C>>[C:18]([C:10]1[C:11]2[C:16](=[CH:15][CH:14]=[C:13]([O:17][CH2:38][C:39]3[N:44]=[CH:43][CH:42]=[CH:41][N:40]=3)[CH:12]=2)[N:8]([CH2:7][C:6]([O:5][C:1]([CH3:2])([CH3:3])[CH3:4])=[O:24])[N:9]=1)#[N:19]参加物
3
実験手順
The title compound was prepared from tert-butyl (3-cyano-5-hydroxy-indazol-1-yl)-acetic acid tert-butyl ester in a similar manner as described in step G of Scheme A4 for the preparation of methyl 2-(3-acetyl-5-(pyrimidin-2-ylmethoxy)-1H-indazol-1-yl)acetate. MS (LC-MS): 366.0 [M+H]+, tR (HPLC conditions e): 4.63 min.
後処理
- custom4.63 min.